Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Biomed Res Int. 2020 Oct 16;2020:7139721. doi: 10.1155/2020/7139721. eCollection 2020.
Bladder cancer is one of the most common urinary malignancies. This study is aimed at providing some promising molecular biomarkers for bladder cancer (BC) by investigating the correlation between C1QTNF6 expression and clinical characteristics as well as prognosis in patients with bladder cancer.
Sequencing profiles of C1QTNF6 mRNA in BC patients were collected to evaluate the distinctive gene expression, between normal bladder mucosa and BC, according to the TCGA and GEO databases. The association between C1QTNF6 expression and the clinical features as well as the disease prognosis was evaluated using two independent cohorts. The expression of C1QTNF6 in normal bladder and BC cells was examined by western blotting and PCR, so the underlying molecular mechanism could be further investigated.
C1QTNF6 mRNA levels were found to be differentially expressed in two independent public cohorts, including the TCGA database and GSE13507 dataset from GEO. The protein and RNA levels of C1QTNF6 in BC cells were both elevated when compared to normal bladder cell lines. High C1QTNF6 expression was detected in advanced T/M stages, pathological grade, and AJCC stage when compared to the low C1QTNF6 expression group. The underlying mechanism related to this differential expression could be explained by cell migration and invasion assays, where bladder cancer cells 5637 and T24 had a significant reduction on migration and invasion ability upon knockdown of C1QTNF6 expression. The low C1QTNF6 expression group presented a more prominent OS advantage over the high-expression group in both TCGA and GSE13507 cohorts. Moreover, the protein content in tissues was further validated using the HPA database and TMA. Survival analyses also indicated that the high C1QTNF6 expression group had an unfavorable OS when compared to the low-expression group.
High C1QTNF6 expression may serve as a predictor of poor prognosis in bladder cancer patients, and the underlying mechanism is possibly associated with changes on cancer cell migration and invasion ability.
膀胱癌是最常见的泌尿系统恶性肿瘤之一。本研究旨在通过探讨 C1QTNF6 表达与膀胱癌患者临床特征和预后的相关性,为膀胱癌提供一些有前景的分子生物标志物。
根据 TCGA 和 GEO 数据库,收集膀胱癌患者 C1QTNF6mRNA 的测序谱,以评估正常膀胱黏膜和膀胱癌之间的差异基因表达。使用两个独立的队列评估 C1QTNF6 表达与临床特征和疾病预后的关系。通过 Western blot 和 PCR 检测 C1QTNF6 在正常膀胱和膀胱癌细胞中的表达,进一步研究其潜在的分子机制。
在两个独立的公共队列中,包括 TCGA 数据库和 GEO 的 GSE13507 数据集,发现 C1QTNF6mRNA 水平存在差异表达。与正常膀胱细胞系相比,膀胱癌细胞系 5637 和 T24 的 C1QTNF6 蛋白和 RNA 水平均升高。与 C1QTNF6 低表达组相比,C1QTNF6 高表达组在晚期 T/M 分期、病理分级和 AJCC 分期中检测到更高的表达。通过细胞迁移和侵袭实验可以解释这种差异表达的潜在机制,在下调 C1QTNF6 表达后,膀胱癌细胞 5637 和 T24 的迁移和侵袭能力显著降低。在 TCGA 和 GSE13507 队列中,C1QTNF6 低表达组的 OS 优势明显高于高表达组。此外,使用 HPA 数据库和 TMA 进一步验证了组织中的蛋白含量。生存分析还表明,与低表达组相比,C1QTNF6 高表达组的 OS 较差。
C1QTNF6 高表达可能是膀胱癌患者预后不良的预测因子,其潜在机制可能与癌细胞迁移和侵袭能力的变化有关。